WHAT IS CLAIMED IS:

1. An aqueous pharmaceutical composition containing no arginine comprising etanercept and a stabilizer to inhibit instability, aggregation, misfolding and/or fragmentation of the etanercept, wherein the stabilizer comprises 2 to 10 mM magnesium.

2. The composition of claim 1, further comprising one or more additional components selected from: a buffer; a tonicity modifier, and an excipient.

3. The stabilized etanercept composition of claim 1 where the formulation elicits long term storage stability as characterized by at least one of:

   SEC analysis at M_3 or T_2 or T_4 of: monomer content greater than 90%; aggregates content of less than 3 wt%; and fragment 3 content less than 5 wt%: and

   HIC analysis at M_3 or T_2, or T_4 wherein the amount of the composition represented by peak 1 of the HIC chromatogram is less than 3 wt.%; the amount of the composition represented by peak 2 of the HIC chromatogram is greater than 80 wt.%; and the amount of the composition represented by peak 3 of the HIC chromatogram is less than 20 wt.%.

4. The stabilized etanercept composition of claim 1 wherein the formulation further comprises; optionally up to 6 wt.% sucrose; 25 to 150 mM NaCl; 1 to 30 mM sodium phosphate; wherein the composition has a pH of 6.0 to 6.6.

5. The magnesium chloride stabilized composition of claim 4 eliciting long term storage stability as characterized by:

   SEC analysis at M_3 or T_2, or T_4 of greater than 90 wt.% monomer content; less than 3 wt.% aggregate(s) content; and less than 5 wt% fragment 3; and

   (b) an HIC analysis at M_3 or T_2 or T_4 wherein the amount of the composition represented by peak 1 of the HIC chromatogram is less than 3 wt.%; the amount of the composition represented by peak 2 of the HIC

chromatogram is greater than 80 wt.%; and the amount of the composition represented by peak 3 of the HIC chromatogram is less than 20 wt.%.

6. The magnesium chloride stabilized composition of claim 5 which elicits long term storage stability as characterized by: an HIC analysis at M_3 or T_2 or T_4 wherein the amount of the composition represented by peak 2 of the HIC chromatogram is greater than or equal to 95 wt.%; and wherein, if peak 3 is present on the HIC chromatogram, the amount of the composition represented by peak 3 is less than or equal to 3 wt.%.

7. The magnesium chloride stabilized composition of claim 5 having, on average, no more than 10,000 subvisible particles per mL having a size greater than 5µm.

8. The magnesium chloride stabilized composition of claim 5 comprising about 50 mg/ml of etanercept; about 10 mM magnesium chloride; 10-30 mM sodium phosphate; less than 150 mM sodium chloride; and less than 3 wt.% sucrose; and having a pH of 6.3 to 6.5.

9. The magnesium chloride stabilized composition of claim 5 comprising about 50 mg/ml of etanercept; about 5 mM magnesium chloride; less than 30 mM sodium phosphate; less than 100 mM sodium chloride; and less than 4 wt.% sucrose; and having a pH of 6.3 to 6.5.

10. The magnesium chloride stabilized composition of claim 5 comprising about 50 mg/ml of etanercept; about 4 mM magnesium chloride; less than 30 mM sodium phosphate; about 100 mM sodium chloride; and about 2.5 wt.% sucrose; and having a pH of 6.3 to 6.5.

11. The magnesium chloride stabilized composition of claim 5 comprising about 50 mg/ml of etanercept; about 10 mM magnesium chloride; less than 30 mM sodium phosphate; less than 100 mM sodium chloride; and less than 5 wt.% sucrose; and having a pH of 6.3 to 6.5.

12. The stabilized etanercept composition of claim 1, wherein the composition, at M_3 or T_2 or T_4 elicits long term storage stability that meets one or both of the following criteria:

(A) stability comparable to or better than commercially available etanercept marketed under the trademark Enbrel®, as measured by (i) SEC analysis of the amounts of aggregate(s), monomer and fragment 3 in the composition (as defined in the specification) and (ii) HIC analysis of amounts of material in the composition corresponding to peaks 1, 2 and 3 of the HIC chromatogram (as defined in the specification); and

(B) an HIC chromatogram in which (i) peak 3 is absent, or essentially absent and (ii) peak 2 represents greater than 95 wt% of the composition; an SEC chromatogram containing essentially no peak corresponding to aggregate(s); and an SEC chromatogram in which the monomer content represents at least 95 wt% of the composition.

WHAT IS CLAIMED IS:

1. An aqueous pharmaceutical composition containing no arginine comprising etanercept and a stabilizer to inhibit instability, aggregation, misfolding and/or fragmentation of the etanercept, wherein the stabilizer comprises 2 to 10 mM magnesium.

2. The composition of claim 1, further comprising one or more additional components selected from: a buffer; a tonicity modifier, and an excipient.

3. The stabilized etanercept composition of claim 1 where the formulation elicits long term storage stability as characterized by at least one of:

   SEC analysis at M_3 or T_2 or T_4 of: monomer content greater than 90%; aggregates content of less than 3 wt%; and fragment 3 content less than 5 wt%: and

   HIC analysis at M_3 or T_2, or T_4 wherein the amount of the composition represented by peak 1 of the HIC chromatogram is less than 3 wt.%; the amount of the composition represented by peak 2 of the HIC chromatogram is greater than 80 wt.%; and the amount of the composition represented by peak 3 of the HIC chromatogram is less than 20 wt.%.

4. The stabilized etanercept composition of claim 1 wherein the formulation further comprises; 0 to 6 wt.% sucrose; 25 to 150 mM NaCl; 1 to 30 mM sodium phosphate; wherein the composition has a pH of 6.0 to 6.6.

5. The magnesium chloride stabilized composition of claim 4 eliciting long term storage stability as characterized by:

   SEC analysis at M_3 or T_2, or T_4 of greater than 90 wt.% monomer content; less than 3 wt.% aggregate(s) content; and less than 5 wt% fragment 3; and

   (b) an HIC analysis at M_3 or T_2 or T_4 wherein the amount of the composition represented by peak 1 of the HIC chromatogram is less than 3 wt.%; the amount of the composition represented by peak 2 of the HIC

chromatogram is greater than 80 wt.%; and the amount of the composition represented by peak 3 of the HIC chromatogram is less than 20 wt.%.

6. The magnesium chloride stabilized composition of claim 5 which elicits long term storage stability as characterized by: an HIC analysis at M_3 or T_2 or T_4 wherein the amount of the composition represented by peak 2 of the HIC chromatogram is greater than or equal to 95 wt.%; and wherein, if peak 3 is present on the HIC chromatogram, the amount of the composition represented by peak 3 is less than or equal to 3 wt.%.

7. The magnesium chloride stabilized composition of claim 5 having, on average, no more than 10,000 subvisible particles per mL having a size greater than 5µm.

8. The magnesium chloride stabilized composition of claim 5 comprising 50 mg/ml of etanercept; 10 mM magnesium chloride; 10-30 mM sodium phosphate; less than 150 mM sodium chloride; and less than 3 wt.% sucrose; and having a pH of 6.3 to 6.5.

9. The magnesium chloride stabilized composition of claim 5 comprising 50 mg/ml of etanercept; 5 mM magnesium chloride; less than 30 mM sodium phosphate; less than 100 mM sodium chloride; and less than 4 wt.% sucrose; and having a pH of 6.3 to 6.5.

10. The magnesium chloride stabilized composition of claim 5 comprising 50 mg/ml of etanercept; 4 mM magnesium chloride; less than 30 mM sodium phosphate; 100 mM sodium chloride; and 2.5 wt.% sucrose; and having a pH of 6.3 to 6.5.

11. The magnesium chloride stabilized composition of claim 5 comprising 50 mg/ml of etanercept; 10 mM magnesium chloride; less than 30 mM sodium phosphate; less than 100 mM sodium chloride; and less than 5 wt.% sucrose; and having a pH of 6.3 to 6.5.

12. The stabilized etanercept composition of claim 1, wherein the composition, at M_3 or T_2 or T_4 elicits long term storage stability that meets one or both of the following criteria:

(A) stability comparable to or better than commercially available etanercept marketed under the trademark Enbrel®, as measured by (i) SEC analysis of the amounts of aggregate(s), monomer and fragment 3 in the composition (as defined in the specification) and (ii) HIC analysis of amounts of material in the composition corresponding to peaks 1, 2 and 3 of the HIC chromatogram (as defined in the specification); and

(B) an HIC chromatogram in which (i) peak 3 is absent, or essentially absent and (ii) peak 2 represents greater than 95 wt% of the composition; an SEC chromatogram containing essentially no peak corresponding to aggregate(s); and an SEC chromatogram in which the monomer content represents at least 95 wt% of the composition.